Scios Inc.

Oncomed Pharmaceuticals, Inc.

California Biotechnology Inc.

Osel, Inc.

Biotechnology Research Associates, J.v.

Scios Nova, Inc.

Leland Stanford Junior University

University of Michigan

John A Lewicki

Austin L Gurney

Timothy Charles Hoey

George Frederic Schreiner

David Y Liu

Sanjeev Satyal

Robert M Scarborough

John J Perumattam

Babu J Mavunkel

J Gordon Porter

Sarvajit Chakravarty

J Jeffrey Seilhamer

Sundeep Dugar

Aaron Sato

Lorin K Johnson

Edward Thein Htun Van Der Horst

Maureen Fitch Bruhns

Wan-ching Yen

Yuan Ching Liu

Qiang Xu

Chia-Hwa Chang

David A Simpson

Theresa Li-Yun Chang

R Richard Goehring

Robert M Scarborough, Jr

Jeffrey J Seilhamer

Michael F Clarke

Gregory R Luedtke

R Tyler White

Alison Joly

Lawrence W Stanton

John H Laragh

Deborah Damm

Xiaowen Liu

Steven A Atlas

Xinhao Wang

Ferid Murad

Brian J McCarthy

Gregory Leudtke

Aaron Ken Sato

An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.

Compositions and methods for diagnosing and treating cancer

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.

Antibodies to a non-ligand binding region of at least two NOTCH receptors

The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3

Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell

Monoclonal antibody that binds human notch2 and notch3

Polynucleotides encoding Notch receptor antibodies

Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1

Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells

An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount.

Methods of treatment by administering antibodies to notch receptors

Antibodies to the NOTCH1 receptor

Nucleic acid molecules encoding soluble frizzled (FZD) receptors

Antibodies to notch receptors

Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2

Growing community of inventors

San Jose, CA, United States of America

John A Lewicki